AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27522631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (or continued low-dose spironolactone)
Number of subjects: 360
Study 24970843 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise programme
Number of subjects: 97
Study 24970843 — intervention group
Group type: COMPARATOR
Intervention: Unspecific exercises (control)
Number of subjects: 97
Study 24970843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 22464071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization (IC)
Number of subjects: 160
Study 22464071 — intervention group
Group type: COMPARATOR
Intervention: Continuous indwelling Foley catheterization (CIF)
Number of subjects: 160
Study 20171415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release 12,000-lipase unit capsules
Number of subjects: 17
Study 20171415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18242141 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1196
Study 18242141 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1196
Study 16025260 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute consultation with the patient's GP and invitation to further GP follow-up
Number of subjects: 91
Study 12938901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐ROM
Number of subjects: 80
Study 12938901 — intervention group
Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 80
Study 11035615 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy with granulocyte-colony-stimulating factor (G-CSF)
Number of subjects: 21
Study 8782425 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceptual salience of dimensions on information boards
Number of subjects: 0
Study 8782425 — intervention group
Group type: EXPERIMENTAL
Intervention: Information constraint
Number of subjects: 0
Study 8782425 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study 1623569 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9% NaCl solution)
Number of subjects: 21
Study 1623569 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (7.5% NaCl solution)
Number of subjects: 21
Study 6370985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (average doses of 150 mg/day)
Number of subjects: 1319
Study 6370985 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (average doses of 150 mg/day)
Number of subjects: 1319
Study 6370985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1319
Study 31594889 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based support (COPD Web) in addition to usual care, a pedometer, and a leaflet about the importance of physical activity.
Number of subjects: 144
Study 31594889 — intervention group
Group type: COMPARATOR
Intervention: Usual care, a pedometer, and a leaflet about the importance of physical activity.
Number of subjects: 144
Study 27709794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg orally)
Number of subjects: 16
Study 27709794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26776677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 142
Study 26776677 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy
Number of subjects: 142
Study 25493035 — intervention group
Group type: EXPERIMENTAL
Intervention: True diet (exclusion diet based on food intolerance tests)
Number of subjects: 38
Study 25493035 — intervention group
Group type: COMPARATOR
Intervention: Control diet (including food items inducing moderate-severe reactions)
Number of subjects: 38
Study 25493035 — intervention group
Group type: COMPARATOR
Intervention: Control diet (after switch to true diet)
Number of subjects: 38
Study 25493035 — intervention group
Group type: EXPERIMENTAL
Intervention: True diet (after switch from control diet)
Number of subjects: 38
Study 22294512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day
Number of subjects: 193
Study 22294512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 21083190 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg
Number of subjects: 0
Study 21083190 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0
Study 21083190 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 21083190 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril and Quinaprilat
Number of subjects: 0
Study 17967675 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 20 mg (IV) twice daily (n = 211)
Number of subjects: 422
Study 17967675 — intervention group
Group type: COMPARATOR
Intervention: placebo (IV) twice daily (n = 203)
Number of subjects: 422
Study 15082970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL)
Number of subjects: 171
Study 15082970 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study 11195891 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing that one's bad mood was frozen (unchangeable)
Number of subjects: 0
Study 9627664 — intervention group
Group type: EXPERIMENTAL
Intervention: EXT‐DCR
Number of subjects: 64
Study 9627664 — intervention group
Group type: COMPARATOR
Intervention: ENL‐DCR
Number of subjects: 64
Study 7931615 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal local-boost radiotherapy and adjuvant chemotherapy with vincristine weekly during radiotherapy followed by eight 6-week cycles of cisplatin, CCNU, and vincristine.
Number of subjects: 63
Study 7931615 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose craniospinal radiotherapy (2400 cGy).
Number of subjects: 63
Study 2979239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil (3 mg b.d.)
Number of subjects: 9
Study 2979239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30100283 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® elastic tape applied for muscle facilitation
Number of subjects: 36
Study 30100283 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® elastic tape applied for muscle inhibition
Number of subjects: 36
Study 30100283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Kinesio Taping® elastic tape)
Number of subjects: 36
Study 28764753 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention involving training videos and a template for conducting an individualised structured medication review.
Number of subjects: 450
Study 28764753 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 450
Study 25362584 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (16 sessions of NFB)
Number of subjects: 24
Study 25362584 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 24
Study 24440473 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (45 Gy in 25 fractions of 1.8 Gy over 5 weeks)
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with concomitant chemotherapy (fluorouracil 350 mg/m² per day intravenous bolus and folinic acid 20 mg/m² per day intravenous bolus)
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (four cycles every 3 weeks)
Number of subjects: 1011
Study 24440473 — intervention group
Group type: COMPARATOR
Intervention: Surveillance after preoperative radiotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with chemotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy and chemotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and adjuvant chemotherapy
Number of subjects: 1011
Study 24440473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adjuvant and neoadjuvant chemotherapy
Number of subjects: 1011
Study 22441231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia online resources (n=8)
Number of subjects: 16
Study 22441231 — intervention group
Group type: COMPARATOR
Intervention: Conventional written material (Control group, n=8)
Number of subjects: 16
Study 19597863 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous TBA (Group A)
Number of subjects: 53
Study 19597863 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial TBA (Group B)
Number of subjects: 53
Study 19597863 — intervention group
Group type: EXPERIMENTAL
Intervention: Submuscular TBA (Group C)
Number of subjects: 53
Study 17498584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 9478
Study 17498584 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 9478
Study 15362015 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (weekly individual sessions for four months)
Number of subjects: 48
Study 11346715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin 40 mg/die for 60 days
Number of subjects: 42
Study 11346715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C vitamin 500 mg/die) for 60 days
Number of subjects: 42
Study 9716008 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 159
Study 9716008 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 159
Study 8732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral nasal allergen challenge
Number of subjects: 6
Study 8732233 — intervention group
Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 6
Study 2252123 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug sequential immunosuppression (Minnesota antilymphocyte globulin, prednisone, azathioprine, and cyclosporine) (n = 107)
Number of subjects: 152
Study 2252123 — intervention group
Group type: COMPARATOR
Intervention: Two-drug sequential immunosuppression (Minnesota antilymphocyte globulin, prednisone, and cyclosporine) (n = 45)
Number of subjects: 152
Study 7027747 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium-albumin (GIKA) infusion
Number of subjects: 50
Study 7027747 — intervention group
Group type: COMPARATOR
Intervention: 5.5% glucose infusion (Control)
Number of subjects: 50
Study 29347863 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus exercise (PE + EX)
Number of subjects: 127
Study 29347863 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation only (PE)
Number of subjects: 127
Study 29347863 — intervention group
Group type: COMPARATOR
Intervention: Usual care attention control (UCAC)
Number of subjects: 127
Study 31072867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy
Number of subjects: 0
Study 31072867 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 0
Study 28329190 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+AIDSVAX B/E
Number of subjects: 162
Study 28329190 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Number of subjects: 162
Study 28329190 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV
Number of subjects: 162
Study 28329190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 25984959 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 20
Study 25984959 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Motivational Interviewing (CAMI)
Number of subjects: 20
Study 25566977 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of piperacillin (PIPC) administered intravenously immediately after endotracheal intubation (Group A)
Number of subjects: 2164
Study 25566977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefazolin (CEZ) administered intravenously immediately after endotracheal intubation (Group B)
Number of subjects: 2164
Study 25566977 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) did not receive AMP
Number of subjects: 2164
Study 21765120 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 188
Study 21765120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 188
Study 19714296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Enzastaurin (GE); E 500 mg p.o. daily; loading-dose (1200 mg; Day 1 Cycle 1 only) and G 1000 mg/m2 i.v. Days 1, 8, and 15 in 28-day cycles
Number of subjects: 130
Study 19714296 — intervention group
Group type: COMPARATOR
Intervention: Single-agent Gemcitabine (G); G as in GE
Number of subjects: 130
Study 18059013 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachea spray
Number of subjects: 0
Study 18059013 — intervention group
Group type: COMPARATOR
Intervention: Molecular water (vaporizing humidifier)
Number of subjects: 0
Study 16824841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 16824841 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg rPSGL-Ig
Number of subjects: 88
Study 16824841 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rPSGL-Ig
Number of subjects: 88
Study 12845504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg) in monotherapy
Number of subjects: 24
Study 12845504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg) with folate (10 mg)
Number of subjects: 24
Study 12845504 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (40 mg followed by 80 mg)
Number of subjects: 24
Study 10685789 — intervention group
Group type: COMPARATOR
Intervention: cA2 monoclonal antibody (1 mg/kg or 10 mg/kg)
Number of subjects: 0
Study 10685789 — intervention group
Group type: COMPARATOR
Intervention: cA2 monoclonal antibody (3 mg/kg or 10 mg/kg)
Number of subjects: 0
Study 10685789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9671161 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 100 microg three times a day
Number of subjects: 15
Study 9671161 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 10 mg three times a day
Number of subjects: 15
Study 10172083 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 40
Study 10172083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2736884 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II; 1 ng min‐1 kg‐1)
Number of subjects: 6
Study 2736884 — intervention group
Group type: COMPARATOR
Intervention: 5% (w/v) D‐glucose (placebo)
Number of subjects: 6
Study 5005719 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (Intal)
Number of subjects: 22
Study 31335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 16 week course of prednisolone (total dose 3150 mg/m2)
Number of subjects: 237
Study 31335316 — intervention group
Group type: COMPARATOR
Intervention: Standard 8 week course of prednisolone (total dose 2240 mg/m2)
Number of subjects: 237
Study 31335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 16 week course of prednisolone
Number of subjects: 237
Study 31335316 — intervention group
Group type: COMPARATOR
Intervention: Standard 8 week course of prednisolone
Number of subjects: 237
Study 28844786 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey questionnaire with paper reminder (N = 2,982)
Number of subjects: 5837
Study 28844786 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire with electronic reminder (N = 2,855)
Number of subjects: 5837
Study 25892528 — intervention group
Group type: EXPERIMENTAL
Intervention: MPE + WG group
Number of subjects: 40
Study 25892528 — intervention group
Group type: COMPARATOR
Intervention: WG group
Number of subjects: 40
Study 23507359 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 183
Study 22037068 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 90
Study 22037068 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 90
Study 18258419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 60
Study 18258419 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 16492212 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine + insulin lispro
Number of subjects: 56
Study 16492212 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin + unmodified human insulin
Number of subjects: 56
Study 14586797 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (300 mg intravenous infusion every 3 weeks for 2 years)
Number of subjects: 30
Study 14586797 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D (active placebo)
Number of subjects: 30
Study 10866444 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-selected grafts
Number of subjects: 40
Study 10866444 — intervention group
Group type: COMPARATOR
Intervention: CD34-unselected grafts
Number of subjects: 40
Study 9268811 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed attention (gaze) at the responding hand
Number of subjects: 0
Study 9268811 — intervention group
Group type: COMPARATOR
Intervention: Looking away from the responding hand
Number of subjects: 0
Study 9268811 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed arm posture with directed attention at the expected side
Number of subjects: 0
Study 9268811 — intervention group
Group type: COMPARATOR
Intervention: Uncrossed arm posture
Number of subjects: 0
Study 7926135 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian diathermy
Number of subjects: 10
Study 7926135 — intervention group
Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian diathermy
Number of subjects: 10
Study 3192670 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused casework approach to the whole family
Number of subjects: 0
Study 3192670 — intervention group
Group type: COMPARATOR
Intervention: Structured play therapy approach to the child
Number of subjects: 0
Study 31192355 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy) and three cycles of FOLFOX4
Number of subjects: 515
Study 31192355 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy with bolus 5-Fu, leucovorin and oxaliplatin)
Number of subjects: 515
Study 31192355 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course/CCT
Number of subjects: 515
Study 31192355 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 515
Study 28316148 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (Group 1; n = 45)
Number of subjects: 90
Study 28316148 — intervention group
Group type: COMPARATOR
Intervention: Linear lesions (Group 2; n = 45)
Number of subjects: 90
Study 28316148 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (Group 1)
Number of subjects: 90
Study 28316148 — intervention group
Group type: COMPARATOR
Intervention: Linear lesions (Group 2)
Number of subjects: 90
Study 25444682 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull
Number of subjects: 16
Study 25444682 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull Light
Number of subjects: 16
Study 25444682 — intervention group
Group type: EXPERIMENTAL
Intervention: Suso Orange
Number of subjects: 16
Study 25444682 — intervention group
Group type: COMPARATOR
Intervention: Control drink (Suso Orange)
Number of subjects: 16
Study 23302264 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoints
Number of subjects: 242
Study 23302264 — intervention group
Group type: COMPARATOR
Intervention: Sham catgut implantation at acupoints
Number of subjects: 242
Study 21345773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzero-balanced ultrafiltration (SBUF)
Number of subjects: 94
Study 21345773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SBUF)
Number of subjects: 94
Study 18583332 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified hMG (hp-hMG)
Number of subjects: 280
Study 18583332 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (rFSH)
Number of subjects: 280
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 0
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 0
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 0
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 0
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10-40 mg/day
Number of subjects: 0
Study 16780391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestyramine 12 g/day
Number of subjects: 0
Study 12932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 42
Study 12932068 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) (Group TIVA)
Number of subjects: 42
Study 10865304 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (2 weeks of in-hospital ergometer exercise for 10 minutes 4 to 6 times per day, followed by 6 months of home-based ergometer exercise training for 20 minutes per day at 70% of peak oxygen uptake)
Number of subjects: 73
Study 10865304 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 73
Study 10865304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 73
Study 9106920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 1619